Article

High expression of WT1 gene in acute myeloid leukemias with more predominant WT1+17AA isoforms at relapse

Department of Hematology, The First People's Hospital of Changzhou, Third Affiliated to Suzhou University, Changzhou, China.
Leukemia research (Impact Factor: 2.36). 05/2009; 34(1):46-9. DOI: 10.1016/j.leukres.2009.04.004
Source: PubMed

ABSTRACT Real-time quantitative reverse transcriptase polymerase chain reaction method was established for detecting the expression levels of WT1 gene and WT1+17AA isoforms in 226 acute myeloid leukemia (AML) bone marrow (BM) cells. The results showed that WT1 gene was 2-3 logarithms expressed more in AML BM cells at initial diagnosis or relapse than in normal BM cells (p<0.001), with predominant WT1+17AA isoforms expression (the ratio of WT1+17AA/WT1 more than 0.50). Interestingly the ratio of WT1+17AA/WT1 was statistically higher in relapsed AMLs than in initially diagnosed (p=0.01), speculating that WT1+17AA isoforms might participate in AML relapse.

0 Bookmarks
 · 
80 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Early stage detection of cancer is the key to provide a better outcome for therapeutic intervention. Most routine screening tools for cancer detection are largely based on examination of cell morphology, tissue histology and measurement of serum markers, which lack sufficient sensitivity and/or specificity for early detection of cancer. Indeed, most secreted proteins studied as cancer screening biomarkers have low sensitivity and/or low specificity and this could be due to the use of non-sensitive techniques or due the fact that several of these tumor markers are also produced by normal tissues. Altogether, these facts pinpoint to the urgent need for the discovery of innovative tools and novel tumour markers for cancer screening, diagnosis, and prognosis. Recently, scientists and clinicians have shifted to innovative techniques in order to identify and characterize biomarkers that drive the development and progression of cancer, and to discover upstream genes/proteins which could be useful to detect early-stage cancer, predict prognosis, determine therapy efficacy, or to be novel drug targets. This chapter contains three sections that will discuss different but complementary innovative techniques that are being developed for the detection of early biomarkers in cancers. The first technique will focus on the use of Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) for the quantitation of the Wilms' tumor gene (WT1) mRNA (WT1 Assay). The WT1 mRNA is a relatively new marker of several types of leukemia and myelodysplastic syndrome (MDS). This WT1 assay makes it possible to rapidly assess the effectiveness of treatment and to evaluate the degree of eradication of leukemic cells as well as the continuous assessment of the MDS progression and its evolution to overt acute myeloid leukemia. The second section will highlight the use of Mass Spectrometry (MS) technique as an important analytical tool in clinical proteomics, primarily in the disease-specific discovery, identification and characterization of proteomic biomarkers and patterns. MS-based proteomics is increasingly being used in clinical validation and diagnostic method development. In this section, we will describe the current state of MS in clinical proteomics applied to early detection of cancer biomarkers with a focus on ovarian and breast cancers including both biomarker discovery and clinical diagnosis. In the last section we will focus on the Surface Plasmon Resonance (SPR) technique which is primarily used to detect bimolecular interaction and has recently gained enormous interest and popularity for its versatility and high sensitivity especially when it is coupled to MS.
    Cancer Biomarkers: Non-Invasive Early Diagnosis and Prognosis, Edited by Debmalya Barh, Angelo Carpi, Mukesh Verma, and Mehmet Gunduz, 10/2013: chapter 4: pages 900; Taylor & Francis/CRC Press., ISBN: 9781466584280
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Wilms' tumor (WT1) gene overexpresses in leukemic cells which is alternatively spliced at two sites, yielding four isoforms: WT1 (+/+), (+/-), (-/+), and (-/-). Curcumin is one of major active components of the spice turmeric, widely known as anticancer. This study investigated the effects and inhibitory mechanism of pure curcumin on WT1 isoform-transfected U937 cells. WT1 transfected U937 cells were initially treated for 24 h, with 10 µM pure curcumin. Pure curcumin exhibited a strong inhibitory effect on WT1 (+/+) mRNA level detected by real time PCR. Treatment of WT1 transfected U937 cells with non-cytotoxic doses (10, 15, and 17 µM) of pure curcumin decreased WT1 protein levels in a dose-dependent manner. Pure curcumin at the concentration of 15 µM significantly decreased the protein levels of the WT (+/+) isoform in a time-dependent manner. It also decreased exogenous WT1 (+/+) protein half-life. WT1 protein expression was inhibited by protein kinase C inhibitor (GF109203x) suggesting that pure curcumin decreased exogenous WT1 (+/+) expression in transfected U937 cells via protein kinase C during post-translational processing.
  • [Show abstract] [Hide abstract]
    ABSTRACT: WT1 plays a dual role in leukemia development, probably due to an imbalance in the expression of the 4 main WT1 isoforms. We quantify their expression and evaluate them in a series of AML patients. Our data showed a predominant expression of isoform D in AML, although in a lower quantity than in normal CD34+ cells. We found a positive correlation between the total WT1 expression and A, B and C isoforms. The overexpression of WT1 in AML might be due to a relative increase in A, B and C isoforms, together with a relative decrease in isoform D expression.
    Leukemia research 10/2013; DOI:10.1016/j.leukres.2013.10.009 · 2.36 Impact Factor